Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Mesothelioma, drawn from the whole corpus: 43 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Sarcomatoid subtype.
No early detection despite known exposure.
Even the best first-line regimens give a median survival under two years; the tail of long survivors on immunotherapy is what to build on.
Epithelioid disease gains little from immunotherapy over chemotherapy; no predictive biomarker beyond histology.
No approved targeted therapy despite recurrent BAP1, CDKN2A/MTAP, and NF2 alterations.
Second-line options are weak once immunotherapy has been used first.
Surgery's role is now unclear for the small group of early, epithelioid, node-negative patients.
Response assessment is hard (modified RECIST for pleural rind); trials are small and slow.
Asbestos is still produced and used in several large countries; incidence will rise there for decades.
Peritoneal and rarer sites lack dedicated evidence.
Also on OnCo: Atlas of advanced disease · How cancer spreads: the metastasis stages.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 33 changes by month →When this page itself was last checked or edited.
CT and PET/CT; thoracoscopic biopsy with IHC panel (calretinin, WT1, D2-40; BAP1 and MTAP loss support malignancy); histology and BAP1/MTAP status recorded for treatment planning. (NCCN MPM guideline)
Stopped early; primary endpoint not met.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.
OS not significantly improved overall; benefit in non-epithelioid subgroup.